Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/the-predictive-and-prognostic-role-of-topoisomerase-ii-agr-and-tissue-BAxnWw0xJ5
References (74)
-
D. Angelucci, N. Tinari, A. Grassadonia, E. Cianchetti, G. Ausili-Cèfaro, L. Iezzi, M. Zilli, S. Grossi, L. Ursini, M. Scognamiglio, G. Castrilli, M. Tursi, P. Noccioli, Pasquale Cioffi, S. Iacobelli, C. Natoli (2012)
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practiceJournal of Cancer Research and Clinical Oncology, 139
-
M. Martín-Richard, M. Muñoz, J. Albanell, L. Colomo, M. Bellet, M. Rey, J. Tabernero, C. Alonso, A. Cardesa, P. Gascón, P. Fernández (2004)
Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based ChemotherapyOncology, 66
-
Harry Bear, S. Anderson, A. Brown, Roy Smith, E. Mamounas, B. Fisher, R. Margolese, Heather Theoret, A. Soran, D. Wickerham, N. Wolmark (2003)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 22
-
V. Durbecq, M. Paesmans, F. Cardoso, C. Desmedt, A. Leo, S. Chan, K. Friedrichs, T. Pintér, S. Belle, E. Murray, I. Bodrogi, E. Walpole, B. Lespérance, S. Korec, J. Crown, P. Simmonds, T. Perren, J. Leroy, G. Rouas, C. Sotiriou, M. Piccart, D. Larsimont (2004)
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.Molecular cancer therapeutics, 3 10
-
K. Nielsen, B. Ejlertsen, S. Møller, Jan Jørgensen, Ann Knoop, H. Knudsen, H. Mouridsen (2008)
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89DActa Oncologica, 47
-
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
-
D. Sataloff, B. Mason, A. Prestipino, Seinige Ul, Lieber Cp, Z. Baloch (1995)
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.Journal of the American College of Surgeons, 180 3
-
J. Coon, E. Marcus, S. Gupta-Burt, S. Seelig, K. Jacobson, Shande Chen, V. Renta, G. Fronda, H. Preisler (2002)
Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 4
-
G. Franceschini, D. Terribile, C. Fabbri, S. Magno, P. D'alba, F. Chiesa, A. Leone, R. Masetti (2007)
Management of locally advanced breast cancer. Mini-review.Minerva chirurgica, 62 4
-
R. Pu, A. Schott, David Sturtz, K. Griffith, C. Kleer (2005)
Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor NecrosisThe American Journal of Surgical Pathology, 29
-
N. Caterina, L. Windsor, Audra Yermovsky, M. Bodden, K. Taylor, H. Birkedal‐Hansen, J. Engler (1997)
Replacement of Conserved Cysteines in Human Tissue Inhibitor of Metalloproteinases-1*The Journal of Biological Chemistry, 272
-
(2005)
Topoisomerase II alpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer -
E. Arriola, S. Rodríguez-Pinilla, M. Lambros, Robin Jones, Michelle James, K. Savage, I. Smith, M. Dowsett, J. Reis-Filho (2007)
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancerBreast Cancer Research and Treatment, 106
-
L. Carey, C. Perou, C. Livasy, L. Dressler, D. Cowan, K. Conway, G. Karaca, M. Troester, C. Tse, S. Edmiston, Sandra Deming, J. Geradts, M. Cheang, T. Nielsen, P. Moorman, H. Earp, R. Millikan (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA, 295 21
-
A. Dechaphunkul, Monlika Phukaoloun, Kanet Kanjanapradit, K. Graham, Sunita Ghosh, Cheryl Santos, J. Mackey (2012)
Prognostic Significance of Tissue Inhibitor of Metalloproteinase-1 in Breast CancerInternational Journal of Breast Cancer, 2012
-
A. González-Angulo, F. Morales-Vásquez, G. Hortobagyi (2007)
Overview of resistance to systemic therapy in patients with breast cancer.Advances in experimental medicine and biology, 608
-
Kyung-Il Park, Juree Kim, Sung-Nam Lim, Sehwan Han (2003)
Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.European journal of cancer, 39 5
-
Wolff (2013)
. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical OncologyCollege of American Pathologists clinical practice guideline update.J Clin Oncol, 1
-
B. Ejlertsen, M. Jensen, K. Nielsen, E. Balslev, B. Rasmussen, G. Willemoe, P. Hertel, A. Knoop, H. Mouridsen, N. Brünner (2010)
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 6
-
Yangfu Jiang, I. Goldberg, Y. Shi (2002)
Complex roles of tissue inhibitors of metalloproteinases in cancerOncogene, 21
-
Ki-Kyung Jung, Xu-wen Liu, Rosemarie Chirco, R. Fridman, H. Kim (2006)
Identification of CD63 as a tissue inhibitor of metalloproteinase‐1 interacting cell surface proteinThe EMBO Journal, 25
-
R. Glynn, S. Mahon, C. Curran, G. Callagy, N. Miller, M. Kerin (2011)
TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.The oncologist, 16 7
-
J. Pierga, E. Mouret, V. Diéras, V. Laurence, P. Beuzeboc, T. Dorval, T. Palangié, M. Jouve, A. Vincent-Salomon, S. Scholl, J. Extra, B. Asselain, P. Pouillart (2000)
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerBritish Journal of Cancer, 83
-
M. Dowsett, S. Ebbs, J. Dixon, A. Skene, C. Griffith, I. Boeddinghaus, J. Salter, S. Detre, M. Hills, S. Ashley, S. Francis, G. Walsh, I. Smith (2005)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
-
R. Tubbs, William Barlow, G. Budd, Eric Swain, P. Porter, A. Gown, I. Yeh, G. Sledge, C. Shapiro, J. Ingle, C. Haskell, K Albain, R. Livingston, Daniel Hayes (2009)
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 24
-
Suada Kuskunović, S. Radović, Mirsad Dorić, Ajna Hukić, M. Babić, I. Tomić, I. Selak (2009)
Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinoma.Bosnian journal of basic medical sciences, 9 2
-
J. Chang, M. Ormerod, T. Powles, D. Allred, S. Ashley, M. Dowsett (2000)
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinomaCancer, 89
-
Sophie Abrial, F. Penault-Llorca, R. Delva, P. Bougnoux, B. Leduc, M. Mouret-Reynier, D. Mery-mignard, J. Bleuse, J. Dauplat, H. Curé, P. Chollet (2006)
High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast CancerBreast Cancer Research and Treatment, 98
-
S. Froelich-Ammon, N. Osheroff (1995)
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*)The Journal of Biological Chemistry, 270
-
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmström, N. Wilking, J. Nilsson, J. Bergh (2006)
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 16
-
Prognostic potential of topoisomerase II a and HER 2 in a retrospective analysis of early advanced -
Sui Zhang, Xiaobing Liu, Tasneem Bawa-Khalfe, Long‐Sheng Lu, Y. Lyu, Leroy Liu, E. Yeh (2012)
Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 18
-
(2010)
Topoisomerase II alpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer -
G. Steger, R. Bartsch (2011)
Trends and Novel Approaches in Neoadjuvant Treatment of Breast CancerBreast Care, 6
-
Abrial (2005)
. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.Breast Cancer Res Treat, 94
-
G. Willemoe, P. Hertel, Annette Bartels, M. Jensen, E. Balslev, B. Rasmussen, H. Mouridsen, B. Ejlertsen, N. Brünner (2009)
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.European journal of cancer, 45 14
-
(2006)
breast cancer subtypes, and survival in the Carolina Breast Cancer Study -
Antonio Wolff, M. Hammond, David Hicks, M. Dowsett, Lisa McShane, Kimberly Allison, D. Allred, John Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, Robert Jenkins, P. Mangu, S. Paik, Edith Perez, Michael Press, Patricia Spears, Gail Vance, G. Viale, Daniel Hayes (2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine, 138 2
-
J. Bartlett, A. Munro, J. Dunn, C. McConkey, Sarah Jordan, C. Twelves, D. Cameron, J. Thomas, Fiona Campbell, D. Rea, E. Provenzano, C. Caldas, P. Pharoah, L. Hiller, H. Earl, C. Poole (2010)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).The Lancet. Oncology, 11 3
-
W. Stetler-Stevenson (2008)
Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological ActivitiesScience Signaling, 1
-
(2010)
TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients -
G. Arpino, D. Ciocca, H. Weiss, D. Allred, P. Daguerre, L. Vargas-Roig, M. Leuzzi, F. Gago, R. Elledge, S. Mohsin (2005)
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancerBreast Cancer Research and Treatment, 92
-
C. Elston, I. Ellis (2002)
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.Histopathology, 41 3A
-
B. Biesaga, J. Niemiec, M. Ziobro, J. Wysocka, A. Kruczak (2011)
Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.Breast, 20 4
-
S. Würtz, A. Schrohl, N. Sørensen, Ulrik Lademann, I. Christensen, H. Mouridsen, N. Brünner (2005)
Tissue inhibitor of metalloproteinases-1 in breast cancer.Endocrine-related cancer, 12 2
-
G. MacGrogan, P. Rudolph, Mascarel Id, L. Mauriac, M. Durand, A. Avril, J. Dilhuydy, J. Robert, S. Mathoulin-Pélissier, Picot, A. Floquet, G. Sierankowski, J. Coindre (2003)
DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancerBritish Journal of Cancer, 89
-
F. Penault-Llorca, C. Abrial, I. Raoelfils, A. Cayre, M. Mouret-Reynier, M. Leheurteur, X. Durando, J. Achard, P. Gimbergues, P. Chollet (2008)
Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.Human pathology, 39 8
-
Frank Murphy, R. Issa, Xiaoying Zhou, S. Ratnarajah, H. Nagase, M. Arthur, C. Benyon, J. Iredale (2002)
Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase InhibitionThe Journal of Biological Chemistry, 277
-
F. Greene, L. Sobin (2002)
The TNM system: Our language for cancer careJournal of Surgical Oncology, 80
-
A. Munro, Annette Bartels, E. Balslev, C. Twelves, D. Cameron, N. Brünner, J. Bartlett (2013)
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Breast Cancer Research : BCR, 15
-
H. Kuerer, L. Newman, T. Smith, F. Ames, K. Hunt, K. Dhingra, R. Theriault, Gurpreet Singh, Susan Binkley, N. Sneige, T. Buchholz, M. Ross, M. Mcneese, A. Buzdar, G. Hortobagyi, S. Singletary (1999)
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 2
-
B. Biesaga, J. Niemiec, Z. Ziobro, J. Wysocka, A. Kruczak (2008)
Biological prognostic factors for disease free survival in breast cancer patients treated with adjuvant anthracycline chemotherapyEjc Supplements, 6
-
P. Fritz, C. Cabrera, Jürgen Dippon, A. Gerteis, W. Simon, W. Aulitzky, Heiko Kuip (2005)
c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective studyBreast Cancer Research, 7
-
S. Giordano (2003)
Update on locally advanced breast cancer.The oncologist, 8 6
-
A. Minisini, C. Loreto, M. Mansutti, D. Artico, S. Pizzolitto, A. Piga, F. Puglisi (2005)
Topoisomerase IIα and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancerCancer Letters, 224
-
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Archives of pathology & laboratory medicine, 134 6
-
S. Würtz, A. Schrohl, H. Mouridsen, N. Brünner (2008)
TIMP-1 as a tumor marker in breast cancer – An updateActa Oncologica, 47
-
P. Watt, I. Hickson (1994)
Structure and function of type II DNA topoisomerases.The Biochemical journal, 303 ( Pt 3)
-
S. Heys, A. Hutcheon, T. Sarkar, K. Ogston, I. Miller, S. Payne, I. Smith, L. Walker, O. Eremin (2002)
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.Clinical breast cancer, 3 Suppl 2
-
Topoisomerase IIa as a predictive factor of response to therapy with anthracyclines in locally advanced -
P. Borgen (2004)
Management of locally advanced breast cancerWorld Journal of Surgery, 18
-
(2016)
DNA topoisomerase IIa expression and the response to primary chemotherapy in breast cancer -
A. Schrohl, M. Gelder, M. Holten-Andersen, I. Christensen, M. Look, H. Mouridsen, N. Brünner, J. Foekens (2006)
Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast CancerClinical Cancer Research, 12
-
W. Cance, L. Carey, B. Calvo, Carolyn Sartor, L. Sawyer, D. Moore, J. Rosenman, D. Ollila, M. Graham (2002)
Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma: Effective Clinical Downstaging Allows Breast Preservation and Predicts Outstanding Local Control and SurvivalAnnals of Surgery, 236
-
P. Hertel, D. Tu, B. Ejlertsen, M. Jensen, E. Balslev, Shan Jiang, F. O'Malley, K. Pritchard, L. Shepherd, Annette Bartels, N. Brünner, T. Nielsen (2012)
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patientsBreast Cancer Research and Treatment, 132
-
Allan Chen, Leroy Liu (1994)
DNA topoisomerases: essential enzymes and lethal targets.Annual review of pharmacology and toxicology, 34
-
M. Colleoni, I. Minchella, Giovanni Mazzarol, F. Nolè, G. Peruzzotti, A. Rocca, G. Viale, L. Orlando, Gianluigi Ferretti, G. Curigliano, P. Veronesi, M. Intra, A. Goldhirsch (2000)
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.Annals of oncology : official journal of the European Society for Medical Oncology, 11 8
-
H. Gómez, J. Pinto, M. Olivera, T. Vidaurre, Franco Doimi, C. Vigil, Raúl Velarde, J. Abugattas, E. Alarcón, C. Vallejos (2011)
Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.Breast, 20 1
-
Ting Wang, K. Yamashita, K. Iwata, T. Hayakawa (2002)
Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways.Biochemical and biophysical research communications, 296 1
-
P. Depowski, Seth Rosenthal, T. Brien, S. Stylos, Rebecca Johnson, J. Ross (2000)
Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome VariablesModern Pathology, 13
-
K. Ogston, I. Miller, S. Payne, A. Hutcheon, T. Sarkar, I. Smith, A. Schofield, S. Heys (2003)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.Breast, 12 5
-
B. Keam, S. Im, Hee-Jun Kim, D. Oh, J. Kim, Se-Hoon Lee, E. Chie, W. Han, Dong-Wan Kim, W. Moon, Tae-You Kim, I. Park, D. Noh, D. Heo, S. Ha, Y. Bang (2007)
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerBMC Cancer, 7
-
J. Donnelly, D. Parham, T. Hickish, H. Chan, A. Skene (2001)
Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer.Breast, 10 1
-
C. Schindlbeck, D. Mayr, C. Olivier, B. Rack, V. Engelstaedter, J. Jueckstock, C. Jenderek, U. Andergassen, U. Jeschke, K. Friese (2010)
Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancerJournal of Cancer Research and Clinical Oncology, 136
- Copyright
- Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
- ISSN
- 1541-2016
- DOI
- 10.1097/PAI.0000000000000154
- pmid
- 25710584
- Publisher site
- See Article on Publisher Site
Abstract
RESEARCH ARTICLE The Predictive and Prognostic Role of Topoisomerase IIa and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy Hala S. El Rebey, MD,* Hayam A. S. Aiad, MD,* Iman L. Abulkheir, MD,w Nancy Y. Asaad, MD,* Moshira M. A. El-Wahed, MD,* Fatma M. Abulkasem, MD,z and Shereen F. Mahmoud, MD* Conclusion: TOP2a and TIMP-1 are important predictive and Purpose: Locally advanced breast cancer (LABC) is a hetero- prognostic factors in LABC patients who received anthra- geneous entity that remains a clinical challenge. Anthracycline- cycline-based chemotherapy. based neoadjuvant chemotherapy has emerged as the standard Key Words: locally advanced breast cancer (LABC), anthra- of care for those patients. However, it is associated with serious cyclines, topoisomerase IIa (TOP2a) and tissue inhibitor of side effects including cardiotoxicity. This study aimed to eval- metalloproteinases 1 (TIMP-1) uate the prognostic and predictive role of topoisomerase IIa (TOP2a) and tissue inhibitor of metalloproteinases 1 (TIMP-1) (Appl Immunohistochem Mol Morphol 2015;00:000–000) in Egyptian LABC patients after anthracycline-based neo- adjuvant chemotherapy. Materials and Methods: This retrospective study was conducted he use of neoadjuvant chemotherapy has emerged as on 84 LABC cases. Immunohistochemical expression of TOP2a
Journal
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Feb 1, 2015